2-((tert-Butoxycarbonyl)amino)isonicotinic acid, 95.0%, 500mg

3H-Oxazolo[4,5-b]pyridin-2-one, 97.0%, 100g

Solución estándar de tungsteno ICP, ROTI®Star, 1000 mg/l W, densidad (D) 1 g/cm³

L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butyn-1-yl]benzoyl]-, 98%, 100mg

4,6-Dichloro-5-nitro-2-(propylthio)pyrimidine, 95.0%, 25g

(5aS,10bR)-2-(2,4,6-Triisopropylphenyl)-5a,10b-dihydro-4H,6H-indeno[2,1-b][1,2,4]triazolo[4,3-d][1,4]oxazin-2-ium tetrafluoroborate, 97%, 1g

Xphos, mínimo 97 %, 5 g, envase de vidrio

3-methylimidazo[1,5-a]pyridine-1-carboxylic acid, >95%, 250mg

5-(4-Fluoro-phenyl)-N-hydroxy-2-methyl-furan-3-carboxamidine, 95.0%, 1g

2-Methyl-2,3-dihydro-1h-indene, 95%, 100mg

ETHYL 7-OXOHEPTANOATE, 97.0%, 100mg

Juego estándar de punto de fusión 3, ROTI®Calipure, 1 juego, envase de vidrio

2,4,6-Trimethylbenzoic Acid>98.0%(GC)(T)10g